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1. Introduction
Despite the progressive decrease observed in the past fifty years, gastric cancer (GC) is the
fourth of the world rankings incidence of various types of cancer and is the second as a cause
of cancer-related death. There is distinct geographical variation in gastric cancer incidence with
the highest rates reported from Japan, Korea and Eastern Asia. Other high incidence areas are
Eastern Europe and parts of Latin America, while Western Europe, Africa, Australia and the
US generally have low incidence rates. In the last decade there has been a downward trend in
the incidence and mortality from this cancer. The reasons are to be found in the improvement
of food both as regards its preservation procedures and the variability in the diet and for the
decrease of infection by Helicobacter pylori (H. pylori). H. pylori infection is strongly associated
with risk for stomach cancer. Likely, this association is supported by the strong link between
this bacterium infections and precancerous lesions, including chronic atrophic gastritis and
dysplasia. The development of gastric cancer is characterized by multistage process in which
several alterations of genetic and epigenetic nature accumulate. These alterations are mainly
related to abnormalities of growth factors and receptors, DNA mismatch repair genes,
angiogenic factors, transcription factors, adaptor proteins, cell cycle regulators, and many
other macromolecular cell components. All these abnormalities identify from one side the
molecular and biological aspect of gastric cancer cells and from the other might suggest
possible strategies for therapeutic intervention.
The most important epigenetic alterations are confined within the chromatin structure like
chromatin remodeling, DNA methylation and histone modification. These molecular altera‐
tions are generally common in gastric cancer, independently from its classification (gastric or
intestinal). Also genetic polymorphism represents a possible endogenous cause of cancer risk.
However, it must be considered that genetic polymorphisms might influence the efficacy of
gastric cancer therapy and the toxicity of anticancer drugs. Although the worldwide decline
in incidence and recent diagnostic and therapeutic advances provided excellent survival for
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patients with early gastric cancer, the prognosis of patients with advances cancer is still poor.
Over the past 15 years, integrated research, including genetic polymorphism and global
analysis of gene expression has clarified detailed molecular mechanisms and the role of genetic
and epigenetic abnormalities of cancer-related genes in the course of development and
progression of gastric cancer. This review describes an outline of the molecular pathway of
stomach carcinogenesis, as signaling pathways, H. pylori, epigenetic and oncogenic back‐
ground of gastric cancer, and recent treatment modalities.
2. Risk factors and classification
The general decrease of gastric cancer frequency in developed countries is attributed to the
changes in dietary habits and food preservation methods [1]. Chronic inflammation with
gastric atrophy was shown to be the most important pathological entity with hypochlorhydria
being the most important physiological abnormality. Alcohol and smoking are also thought
to contribute to the etiology. Achlorhydria, pernicious anaemia and blood group A are also
associated with a higher risk of gastric malignancy. However, following the discovery of H.
pylori it is known that more than 80% of gastric cancer cases can be attributed to deregulation
of signaling pathways caused by H. pylori infection [2]. Genetic syndromes are rare and families
clustering of gastric cancer are usually attributed to common H. pylori infection. A family
syndrome of gastric cancer due to germ-line mutation in E-cadherin has been described, and
gastric cancer may be part of Lynch syndrome (HNPCC). Mutations and polymorphism of
interleukin 1β (IL-1β) and Tumor Necrosis Factor α (TNFα) have been described in closer
relatives of patients affected by gastric cancer, and considered predictive factors for cancer.
Genetic polymorphism is an important endogenous cause and modulator of risk for develop‐
ing gastric cancer. They include: 1) inflammatory responses to H. pylori infection such as
variants of IL-1β and IL-1 receptor antagonist (IL-RA); 2) intrinsic variability of DNA repair
processes; 3) function of carcinogen detoxification and antioxidant protection; 4) cell prolifer‐
ation activity [3].
GC is characterized by two distinct histological type of adenocarcinoma (intestinal type and a
diffuse type) each having different epidemiological and pathophysiological features [4]. The
intestinal-type generally evolves through a relatively well-defined multistep process that starts
from chronic gastritis and progresses to chronic atrophy, intestinal metaplasia and dysplasia
[5, 6]. It is associated with H. pylori infections and certain dietary factors, such as high intake
of salt, smoked meats and food preserved with nitrites or nitrates [7, 8]. Intestinal tumors
consist of malignant cells that resemble functional glands of the gastrointestinal tract. They are
well differentiated and occur more commonly in older patients, males and blacks. The diffuse-
type has instead a poorer prognosis and develops from normal gastric epithelium through
unknown genetic and morphological events. It comprises cells that lack cohesion and are no
longer capable of gastric function and it is more frequent in younger patients [9]. Several
common events are shared between the two histological GC subtypes whereas distinct
differences also highlight the intriguing divergence in histogenesis. The etiology of these
differences remains to be elucidated [10, 11].
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3. H. pylori infection
The pathogenesis of gastric cancer remains poorly understood although it is evident that
several environmental factors, such as H. pylori infection can be the cause leading to this
disease.
H. pylori infection is associated with risk for both the intestinal and diffuse varieties of gastric
cancer. In fact, the risk to develop gastric cancer is increased in patients with H. pylori infections
probably as the result of a combination of genetic and environmental factors in which the
infection by H. pylori is of particular relevance, especially when the inflammation involves the
gastric body region with respect to the antrum [6, 12, 13]. Generally, this condition is associated
to different degrees of atrophy and alterations of the secretory function that, in the long term,
became associated to gastric carcinoma [14-16]. The positive correlation between H. pylori
infection and development of gastric cancer is well established and proven in prospective
controlled studies [17, 18], whereas in absence of infection, development of gastric carcinoma
constitutes a rare event. Furthermore eradication of H. pylori leads to a substantial reduction
the risk of gastric cancer. From a pathogenetic point of view, it is believed that H. pylori infection
determines the release of free radicals, resulting in mitogen stimulation and the inflammatory
response of the stomach epithelium. The pathogenesis is associated with two bacterial genes
known as CagA (Cytotoxic Associated Gene-A) and VacA (Vacuolating cytotoxin gene-A).
The CagA gene is a marker for about twenty genes capable of increase the turnover of gastric
epithelium through the CagA protein release. As a result, the association with an increased
risk of developing non-cardia gastric cancer seems to be associated to H. pylori strain CagA
[19]. A key role seems to have the so-called nuclear factor kB (NF-kB) [20]. NF-kB activation
is in fact not only limited to patients with H. pylori active infection,but its nuclear and cyto‐
plasmic expression appears to be up-regulate in gastric adenocarcinoma compared to adjacent
normal tissue. The key role that this protein plays is also confirmed by the correlation between
its expression and tumor conditions: biological and clinical aggressiveness, lymphatic
invasion, tumor size and metastasis [21].
Among the targets of CagA strain there is also RUNX3, a tumor suppressor in many tissues and
frequently inactivated in gastric cancer. Recently, it has been shown that H. pylori infection
inactivates RUNX3 in CagA-dependent manner: CagA directly associates with RUNX3 through
the specific recognition between the PY motif of RUNX3 and the WW domain of CagA [22].
4. Molecular pathology
The bacterial, environmental and host genetic factors discussed above influence the develop‐
ment of gastric carcinoma. Genomic, proteomic and biotechnology could allow the identifi‐
cation of novel genes and molecules specifically up-regulated or down-regulated in gastric
cancer. Advances in our understanding of the genetic and molecular bases of gastric cancer
lead to improved diagnosis, personalized medicine and prevention of gastric cancer.
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In the following section, we discuss some of the molecular mechanisms underlying the
molecular pathway of stomach carcinogenesis and of the biological and clinical roles of
recently identified genes involved in gastric cancer.
4.1 GKN1
Recently, a novel tissue-specific protein, gastrokine1 (GKN1), has been isolated from gastric
mucosa cells of several mammalian species, including mouse [23]. The human GKN1 gene has
been localized in a 6 kb region of the chromosome 2p13 and contains 6 exons [24]. GKN1 is
found within the granules just under the apical plasma membrane, suggesting that it is a
secreted rather than a membrane protein. GKN1 has been hypothesized to play an important
role in maintaining the integrity of the gastric mucosa and mediating repair after injury. Oien
et al. [25] demonstrated, by Northern blotting, that GKN1 mRNA was abundant only in normal
human stomach, in all areas (cardia, body and antrum), but absent in gastric adenocarcinomas;
gastro-oesophageal adenocarcinoma cell line and other normal and tumor gastro-intestinal
tissues. Therefore, there is a transcriptional silencing of GKN1 gene in gastric cancer. Rippa et
al. [26] recently demonstrated, by means of proteomic technology, that GKN1 protein is
reduced in patients with H. pylori-positive chronic gastritis. In addition, from the analysis of
28 patients with gastric cancer, Nardone et al. [27, 28], showed the downregulation or the
complete absence of the protein. Similarly, Shiozaki et al. [29] showed that transfection with
GKN1 reduced colony formation in MKN-28 gastric carcinoma cells. These data suggest that
GKN1 participates in the host response to H. pylori and may also function as gastric tumor-
suppressor gene [30]. More recently, new interesting data about GKN1 are emerging. Jung
Hwan Yoon et al. [31] observed in GKN1-transfected AGS cells the inhibition of the epithelial–
mesenchymal transition (EMT), a biological process that allows a polarized epithelial cell to
undergo multiple biochemical changes that enable it to assume a mesenchymal cell phenotype,
including enhanced migratory capacity, invasiveness, and elevated resistance to apoptosis.
Also, GKN1-transfected and recombinant GKN1-treated AGS cells showed decreased levels
of reactive oxygen species (ROS) and of phosphatidylinositol 3-kinase (PI3K)/Akt pathway
proteins, which are a major cascade mediating tumor metastasis, accompained by re-expres‐
sion of E-cadherin (a cell adhesion molecule which prevents EMT) and decreased expression
of cytoplasmic and nuclear b-catenin, slug, snail, fibronectin, and vimentin (EMT-related
proteins). These data suggest that the GKN1 gene may play an important role in the progres‐
sion of sporadic gastric cancers via inhibition of EMT and cancer cell migration. Xing et al. [32]
showed instead that GKN1 is an autocrine/paracrine protein that inhibits cell growth due to
senescence resulting from activation of p16/Rb and p21waf pathways. Furthermore, sustained
activation of Ras/Raf/MEK/ERK signalling was characterised in gastric cancer cells and
xenograft nude mouse model following GKN1 treatment. Therefore, this study provides
molecular evidence that GKN1 induces also senescence of gastric cancer cells.
Our group has been studying the effect of GKN1 on gastric cancer cell lines (AGS and MKN28).
We found by cytofluorimetry, Western blot and RT-PCR that overexpression of GKN1 in these
cell lines stimulated the expression of Fas receptor. Moreover, compared to control cells, a
significant increase of apoptosis, evaluated by TUNEL, was observed when GKN1 transfected
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cells were treated with a monoclonal antibody (IgM) anti-Fas. The activation of Fas expression
was also observed by the overexpression of GKN1 in other cancer cell lines. GKN1-overex‐
pressing gastric cancer cells exposed to FasL induced the activation of caspase-3 was as
evaluated by Western blot and fluorescence assays [33]. In addition, MTT assay showed that
recombinant GKN1 reduced cell proliferation of gastric cancer cells (AGS) compared to human
embryonic kidney cell line (HEK 293) and non-gastric cancer cells, human lung epidermoid
carcinoma cell line (H1355). Our data represent the first report for GKN1 as modulator of
apoptotic signals and suggest that GKN1 might play an important role for tissue repair during
the early stages of neoplastic transformation. In fact, it was seen that individuals with a lower
expression of the protein have an increased risk to develop gastric diseases [34].
Figure 1. Effects of GKN1 on cell growth. AGS cell growth was evaluated using the MTT procedure after incubation of
the cells with recombinant GKN1 at different times and concentrations. The data reported represent the average of
three independent experiments.
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Finally, regarding the mechanism by which GKN1 gene is silenced in gastric cancer, this
remains still unknown however, Hwan Yoon et al. [35] investigated this aspect in a sample
group of 81 gastric carcinomas and 40 gastric adenomas: no mutation was detected in gastric
tumours, hyper-methylation of GKN1 gene promoter was found only in two tumours and DNA
copy number of GKN1 was significantly decreased in gastric cancer. However, epigenetic
mechanisms could also contribute to silencing GKN1 gene. Under this aspect, it would be
important to clarify the causes of GKN1 gene silencing and to determine whether this event
might be involved in the development and progression of gastric cancer. Additional functional
and translational studies of GKN1 will broaden our understanding of the pathogenesis of
gastric cancer, and provide us with novel diagnostic and therapeutic modalities in gastric
cancer.
4.2 E–cadherin and the Wnt system
The signal transduction pathway called Wnt is a central mechanism for regulating gene
expression and is highly conserved in vertebrates and invertebrates. It includes a large family
of ligands and plays a key role in many cellular processes, which ranging from regulation of
embryogenesis control processes the proliferation of mature cells. In particular, it seems
crucially involved in the processes of differentiation and proliferation of stem cell elements
[36]. Central to these mechanisms is the process of regulation of expression of the β-catenin,
an intracellular protein able to communicate on the surface of the cell with the system of
cadherine, but also to act as nuclear transcription factor, including the Wnt/Wingless, epider‐
mal growth factor (EGF), hepatocyte growth factor (HGF), and insulin-like growth factor (IGF)
signaling pathways [37-40].
The Wnt signalling pathway can be activated trough the binding of Wnt ligands to their
receptors Frizzled (Fz) and low-density lipoprotein receptor-related protein LRP5 and LRP6
(Figure 2). The binding induces an activation signal direct protein Dishevelled (DSH) and axin,
that once activated, inhibit GSK3 kinase. Normally GSK3 phosphorylates β-catenin as part of
a multiprotein complex that includes GSK3, APC and axin. The phosphorylation triggers the
degradation of β-catenin through the process of ubiquitination (Figure 2, left panel). It follows
that the inhibition Wnt-induced GSK3 interferes with the process of degradation of β-catenin
and causes its cytoplasmic accumulation in a non-complexed form [41]. As consequence, β-
catenin goes into the nucleus and regulates target gene transcription through association with
the transcription factor TCF/ LEF (lymphoid enhancer binding factor) (Figure 2, right panel).
The translocation into the nucleus of β-catenin eventually leads to transcription of several
genes including protagonists of carcinogenesis known protooncogenes such as c-myc and
cyclin D1. In this regard, it is interesting that GSK3 can be inhibited through the PI3K/AKT
pathway after toxin VacA stimulation [42]. This is a further element to support the correlation
between infection by H. pylori and gastric carcinogenesis. Cell adhesion molecules may act as
tumour suppressors such as E-cadherin whose gene is mutated in about 50% of diffuse type
gastric carcinoma [43]. This homophilic cell adhesion molecule belongs to a family of cell-cell
adhesion molecules with an important role in intercellular adhesion by establishing cell
polarity, maintaining tissue morphology and cellular differentiation in normal cells [44, 45].
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E-cadherin binds to the actin cytoskeleton via a series of catenin proteins [46]. Therefore
changes in E-cadherin expression have a direct effect on cell adhesion and therefore plays an
important step in cancer development. Mutations in β-catenin and γ-catenin have also been
observed in gastric cancer cell lines, and together with E-cadherin mutations appear to be
involved in the development and progression of diffuse and schirrhous type cancers [47-49].
As the E-cadherin is responsible for the seizure of a major fraction of β-catenin in the com‐
partment intracellular membrane, a loss of E-cadherin complexed to the cell membrane is
associated with an increase in the share intracytoplasmic and nuclear of β-catenin [50]. In fact,
this possibility is confirmed by immunophenotypic analysis of tumor diffuse gastric, where it
often shows the increasing of nuclear β-catenin expression is associated with reduced of
immunolocalization of membrane of the E-cadherin [51]. Recent data indicate that the simple
down-regulation of E-cadherin, also obtained through epigenetic mechanism, alone would be
sufficient to trigger the molecular carcinogenesis diffuse type of gastric cancer [52]. Despite
the alterations of the E-cadherin seem limited to diffuse forms, also in carcinoma of intestinal
type are observed alterations of the Wnt pathway that leads to an increase of cytosolic and
nuclear β-catenin [53]. This accumulation of β-catenin can be explained by mutations in APC
gene (Adenomatous Polyposis Coli) or in β-catenin gene itself. Both the situations lead to a
Figure 2. The Wnt signaling pathway. In the absence of Wnt ligand (left panel), the destruction complex (GSK3β, APC,
Axin) creates a hyperphosphorylated β-catenin, which is a target for ubiqitination and degradation by the proteo‐
some. Binding of Wnt ligand to a Frizzled/LRP-5/6 receptor complex (right panel) leads to stabilization of hypophos‐
phorylated β-catenin, which interacts with TCF/LEF proteins in the nucleus to activate transcription. β-catenin
normally binds to the intracellular domain of E-cadherin but the whole Wnt pathway is independent of E-cadherin
expression.
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hypophosphorylation of β-catenin, which reduces its proteolytic degradation. This is again an
accumulation of intracytoplasmic β-catenin resulting in its nuclear translocation, where it can
exert oncogenic role. A mutation of the APC gene appears be found in approximately 30% of
adenocarcinomas of type intestinal [54]. To further support the role of Wnt, has observed that
patients with germline mutations of APC present a risk of developing gastric cancer 10 times
higher than that of the normal population [55].
4.3 RUNX3
Another potential candidate in the molecular carcinogenesis process of stomach cancers is
represented by RUNX3, one of the first identified members of the RUNX family (mammalian
Runt related genes) [56]. The RUNX gene family is composed of three members, RUNX1/
AML1, RUNX2 and RUNX3 [57]. These are genes coding for a group of closely related proteins
with DNA binding function. In humans, loss of RUNX3 by hypermethylation of the promoter
CpG islands is observed in several different cancers, including 64% of gastric carcinomas [58].
This loss reaches 90% in patients with gastric cancer in advanced stage. Gastric epithelium of
RUNX3 knockout mice exhibits hyperplasia, reduced rate of apoptosis and reduced sensitivity
to TGFβ1, thus suggesting that the tumour suppressor activity of RUNX3 operates down‐
stream of the TGFβ signaling pathways. RUNX3 methylation is also a feature of 8% of chronic
gastritis, 28% of intestinal metaplasia and 27% of gastric adenomas. These observations suggest
RUNX3 is a target for epigenetic gene silencing in gastric carcinogenesis [59, 60]. Another
element of great interest that correlates RUNX3 to H. pylori infection is represented by the fact
that the H. pylori infection may down-regulate RUNX3 with an epigenetic mechanism [61]. In
fact, it has been observed that during H. pylori infection there is the induction of nitric oxide
production by macrophages resulting in methylation of the RUNX3 promoter. Recent results
also show how the loss of expression of RUNX3 correlatessignificantly with the metastatic
spread of cancer by adversely affecting the prognosis [62].
4.4 Genomic instability
In gastric cancer the loss of genomic stability represents a key molecular step that occurs early
in the carcinogenesis process and creates a permissive environment for the accumulation of
genetic and epigenetic alterations in tumor suppressor genes and oncogenes. It iswidely
accepted that gastric cancer can follow at least two major genomic instability pathways,
chromosome instability (CIN) and microsatellite instability (MSI). CIN is defined as the loss
of chromosomal material during dysfunctional chromosome replication, repair or segregation
[63]. MSI, which results from an erroneous DNA mismatch repair system, has been well known
to be involved in the carcinogenesis of hereditary nonpolyposis colon cancers and some of
sporadic colorectal cancers [64, 65]. A variable fraction from 15% to 50% of sporadic gastric
cancer ischaracterized by MSI as a result of genetic inactivation or mainly Mismatch Repair
(MMR) genes epigenetics, including hMLH1 and hMSH2. The inactivation of MMR genes is
not itself a transforming event and additional genetic changes are required for progression to
malignancy. In particular, in gastric cancer MSI is observed with the presence of mutations in
repetitive sequences of genes involved in the regulation of cell growth (TGF-βRII, IGF-IIR), in
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apoptosis (BAX) and DNA repair (hMSH6, hMSH3). These mutations can alter the gene
expression and give an advantage in cell growth and in clonal expansion. GC with MSI
represents a tumor subset with clinico-pathological specific features. In particular, MSI GC is
an intestinal gastric cancer, with antral location, low prevalence of vascular invasion or lymph
node infiltration and better prognosis.
5. The molecular aspect of gastric cancer as rational for new therapeutic
targeted strategies
In recent years it has strengthened the tendency to identify therapeutic strategies different
from classical chemotherapeutic approach. The reviewed signaling pathways are relevant
contributors for gastric carcinogenesis and encompass a multitude of potential therapeutic
targets. In particular, there are growing efforts designed to identify the molecular mechanisms
whose inhibition can significantly reduce the clinical aggressiveness of tumor malignacy. This
innovative approach has achieved major successes in rare neoplastic diseases such as chronic
myeloid leukemia and gastrointestinal stromal tumors (GIST) where it was possible to
effectively inhibit constitutionally activated receptor tyrosine kinase such as the KIT gene [66,
67]. Except for the inhibition of HER2 in breast carcinoma, the same success has not yet been
achieved in other tumors hence the need to further investigate on the existence of new potential
molecular targets. Under this aspect, GC is not an exception indeed it represents a disease for
the possible application of targeted therapies.
5.1 HER 2
HER2 (Human Epidermal Growth Factor Receptor 2) also known as Neu, ErbB-2, CD340
(cluster of differentiation 340) or p185 is part of a large family of receptors of tyrosine kinase
activities. Along with HER1, also known as EGFR, up-regulation of HER2 is an important event
in molecular carcinogenesis of many cancers. Ligand binding to EGFR extracellular domain
leads to its activation, with subsequent homodimerization leading to the phosphorylation of
its intracellular tyrosine kinase domain. This will initiate a series of intracellular signals,
including activation of the central Ras/Raf/mitogen activated protein kinases (MAPK) signal‐
ing pathway (Figure 3). Up to now, the best model known is constituted by breast carcinoma
in which HER2 is amplified in about 20% of cases [68]. This amplification is correlated to an
increase of the expression of the protein and thus in growth advantage [69]. The prognostic
negative role played by the amplification of HER2 in breast cancer is balanced by the possibility
to interfere with that oncogenetic mechanism through the use of molecular therapies targeted
with humanized monoclonal antibodies (i.e. Trastuzumab) [70]. On the basis of the results
obtained in the treatment of breast cancer and counting on the fact that gastric carcinomas
show amplification of HER2 in approximately 20% of cases, clinical trials have been designed
that demonstrated significant improvement in progression-free survival disease for patients
with HER2 overexpression, treated with trastuzumab, particularly when associated to
conventional chemotherapy [71-73]. It is interesting to note how the aberrations of HER2 are
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practically exclusive of gastric (and cardial) adenocarcinomas of intestinal type, while they are
decidedly not represented in the forms of the diffuse type. As in the case of E-cadherin
alterations, there is a correlation between morphological and molecular mechanism in the
diffuse forms. The EGFR/MAPK pathway has also shown to be activated in gastric carcinomas
with microsatellite instability [74].
Figure 3. HER2 signaling pathway. Binding of EGF to HER2 initiate a series of intracellular signals, including activation
of the central Ras/Raf/mitogen activated protein kinase (MAPK) signaling pathway.
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5.2 VEGF
The mechanisms of angiogenesis have recently received a lot of interest in oncology and the
inhibition of tumor angiogenesis has become a therapeutic option even feasible in gastric
cancer [75]. The vascular endothelial growth factor (VEGF) is a dimeric heparin-binding
glycoprotein and it is characterized by the ability to exert a powerful mitogenic action on
endothelial cells, promoting their growth both in the primary tumor and in metastases, in the
latter case after having stimulated the migration from home neoplastic primitive and secon‐
dary levels. A very recent study has shown a direct relationship between VEGF concentrations
and new blood vessel development; gastric mucosal neovascularization was also reported to
be significantly higher in the antrum of patients with H. pylori-positive gastritis versus non-
infected individuals [76]. Experimental studies using different approaches clearly demonstrate
that VEGF promotes tumor growth, angiogenesis, and metastasis formation [77, 78]. Overex‐
pression of VEGF levels has been actually observed in the serum of gastric cancer patients
compared with normal control and the increase of the expression seems to be correlated with
the tumor stage and mass and is a negative prognostic factor [79]. However, there are limited
data regarding the clinical and prognostic significance of serum VEGF (sVEGF) levels in gastric
cancer patients. The fact that for some years it was possible to interfere with the neoangiogen‐
esis using a recombinant humanized antibody directed against VEGF (bevacizumab) consti‐
tutes an element of great clinical interest. Recent is a publication of data from the first Phase
II study conducted on patients with advanced or metastatic gastric cancer treated with a
combination of bevacizumab, docetaxel and oxaliplatin. Using primary endpoint of progres‐
sion-free survival, complete responses were observed in 5%, partial response in 37% and
stabilization of disease in another 37% of cases. These data certainly encourage randomized
trials to definitively clarify whether the inhibition of angiogenesis can be a very effective way
in the treatment of gastric cancer.
5.3 mTOR
The mammalian target of rapamycin (mTOR) pathway has become a major focus of preclinical
and clinical cancer research [80]. mTOR is a central regulatory kinase that increases the
production of proteins involved in key cellular processes such as cell growth and proliferation,
cell metabolism, and angiogenesis [81-83]. mTOR increases translation of proteins that drive
cell growth and cell division, such as cyclin D1, and decreases translation of negative regulators
of cell cycle progression [84]. It plays a role in cellular metabolism too by stimulating the surface
expression of nutrient transporters [85]. mTOR consists in a double molecular complex
(mTORC1 and mTORC2). mTORC1 is regulated by two components of the complex tuberous
sclerosis (TSC1 and TSC2), which are controlled by the PI3K/AKT. mTORC2 instead regulates
AKT cascade. Recently, because of their function in cell proliferation, these molecular com‐
plexes were considered ideal target for the design of drugs in oncology [86].
The efficiency of this approach has obtained a first success in a group of rare tumors known
as PEComi [87]. However, significant results seem to be possible in the context of solid tumors.
In fact, recent data show that the activation of mTOR in gastric cancer represents a key event
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observed in approximately 50% of cases [88]. Hence, the first attempts to use mTOR inhibitors
to improve the efficiency of systemic therapies [89, 90].
6. Conclusions
In this review, we have summarized reports on genes, proteins and factors involved in gastric
carcinogenesis based on currently available literature. Gastric carcinoma results from a
complex interaction between bacterial, environmental, host-genetic and molecular mecha‐
nisms. It is evident that gastric cancer is the consequence of a multistep process involving
different genetic and epigenetic changes in numerous genes. Host genetic background and
environmental factors also play an important role in the pathogenesis of the disease. The
majority of genetic alterations contributing to the malignant transformation were observed in
growth regulatory genes, and in genes involved in cell cycle progression and arrest. In recent
years, the analysis of molecular carcinogenesis gastric epithelial neoplasm has certainly
provided information of great importance. It is understood that the molecular mechanisms
involved in carcinogenesis of intestinal type are different from those prevailing in the devel‐
opment of diffuse one. The element of greater importance from a clinical point lies in the fact
that the elucidation of these mechanisms is the prerequisite for exploring innovative thera‐
peutic approaches. While the conventional forms of treatment seem to have reached the limit
of effectiveness, it is possible that use of targeted therapies based on solid preclinical rational
can translate into tangible clinical benefit. The reviewed signaling pathways are relevant
contributors for gastric carcinogenesis and encompass a multitude of potential therapeutic
targets. In addition to these signaling-related targets we included new data on
GKN1 as being involved in gastric cancer susceptibility phenotype.
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